483
Leadiant Biosciences, Inc.Leadiant Biosciences, Inc. – FDA 483, Jul 8, 2021
Record Details
Leadiant Biosciences, Inc. in Gaithersburg, MD, was inspected regarding post-marketing adverse drug experience reporting. The inspection revealed that the company failed to submit periodic reports for non-alert adverse drug experiences for an application approved three or more years ago. Specifically, over 300 adverse events for the drug Matulane were incorrectly reported as expedited individual case safety reports instead of periodic safety update reports.
View Company Profile
ID · 3f06dbcb-4c69-4c7b-aa8e-17848c42b8d4
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.